Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PF
Profusa, Inc. Common Stock
PFSA
Mkt Cap
$567,491
Volume
115.90K
Next Earnings
November 18th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PF
PFSA
PF
Profusa, Inc. Common Stock
PFSA
News
·
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
Mkt Cap
$648,042
Volume
115.90K
Next Earnings
November 18th
Chart
Financials
Earnings
News
About
Insider
Filings
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
Profusa has submitted a comprehensive response package to its European Notified Body GMED following successful completion of Stage 1 and Stage 2 assessments for CE Mark certification of its Lumee Oxygen Platform. The submission includes updates to technical documentation, quality system evidence, clinical evaluation activities, and validation information. The company remains committed to obtaining CE Mark certification to support European commercialization of its tissue oxygen monitoring technology.
GlobeNewswire Inc. · Jun 12, 2026
Profusa Receives Favorable Nasdaq Listing Determination
Profusa, Inc. (PFSA) has been granted approval by the Nasdaq Hearings Panel to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market. The company must satisfy interim milestones and comply with bid price and stockholders' equity requirements by July 6, 2026, to maintain its continued listing.
GlobeNewswire Inc. · May 8, 2026
What's Going On With Profusa Stock Tuesday?
Profusa (NASDAQ: PFSA) shares plummeted 40.27% on Tuesday following the announcement of a Letter of Intent to acquire BioInsights' PanOmics multi-omics diagnostics platform for approximately $30 million in an all-equity deal. The acquisition marks Profusa's strategic expansion into molecular diagnostics and aims to complement its Lumee real-time biochemistry monitoring system, with initial commercialization targeting pancreatic cancer.
Benzinga · Apr 7, 2026
Profusa Stock Soars On Deal Targeting Multi Billion Precision Diagnostics Space
Profusa announced an all-equity acquisition of BioInsights LLC's PanOmics multi-omics diagnostics platform, expanding into precision diagnostics. The deal adds $30 million to shareholder equity and accelerates commercialization through integration with Profusa's Lumee platform. The company is also advancing a Mayo Clinic collaboration for pancreatic cancer applications. Profusa shares surged 134.99% in premarket trading.
Benzinga · Apr 6, 2026
Profusa Bolsters European Commercial Network with New French Distributor, MedSell
Profusa announced a new distributor partnership with MedSell in France to commercialize its Lumee Oxygen tissue monitoring device for critical limb threatening ischemia (CLTI) patients. This partnership, combined with existing distributors across Europe, now covers approximately 200,000 annual CLI cases in the EU. The company projects $0.5-$2 million revenue in 2026 and $9-$13 million in 2027, with plans to reach $200-$250 million by 2030.
GlobeNewswire Inc. · Dec 31, 2025
Profusa Announces Third Quarter Business and Financial Highlights
Profusa completed a merger with NorthView Acquisition Corporation, reduced net debt to $14 million, and is preparing to launch its Lumee Oxygen tissue monitoring platform in Europe in early 2026, with potential revenue targets of $0.5-$2 million in 2026 and $9-$13 million in 2027.
GlobeNewswire Inc. · Nov 19, 2025
Profusa Announces $100 Million Equity Line of Credit to Initiate Bitcoin Treasury Strategy
Profusa, a digital health company, is initiating a Bitcoin treasury strategy by executing a Securities Purchase Agreement with Ascent Partners Fund LLC to purchase up to $100 million in common stock, with proceeds intended to be used for Bitcoin acquisition.
GlobeNewswire Inc. · Jul 21, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
PF
PFSA
Profusa, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
PFSA
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any PFSA yet.
Related Tickers
Earnings